Humacyte Inc.’s bioengineered blood vessel technology has received U.S. Food and Drug Administration approval for an investigational new drug application to conduct a multi-center U.S. clinical trial. The company hopes the vessels will help provide better access for dialysis in End-Stage Renal Disease patients.
Thursday, May 2, 2013
Durham Company Aims to Change Kidney Dialysis Process
Humacyte Inc.’s bioengineered blood vessel technology has received U.S. Food and Drug Administration approval for an investigational new drug application to conduct a multi-center U.S. clinical trial. The company hopes the vessels will help provide better access for dialysis in End-Stage Renal Disease patients.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment